Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls

Summary. Aim: Several studies evaluated the association between rs11077 polymorphism located in the 3’UTR of the XPO5 gene and cancer susceptibility. We conducted a meta-analysis to assess the impact of XPO5 rs11077 polymorphism on cancer risk. Materials and Metho...

Full description

Saved in:
Bibliographic Details
Date:2023
Main Authors: Moazeni-Roodi, A., Taheri, M., Hashemi, M.
Format: Article
Language:English
Published: PH Akademperiodyka 2023
Subjects:
Online Access:https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-13
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Experimental Oncology

Institution

Experimental Oncology
id oai:ojs2.ex.aqua-time.com.ua:article-223
record_format ojs
spelling oai:ojs2.ex.aqua-time.com.ua:article-2232023-10-11T16:42:06Z Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls Moazeni-Roodi, A. Taheri, M. Hashemi, M. cancer, meta-analysis, risk, XPO5 cancer, meta-analysis, risk, XPO5 Summary. Aim: Several studies evaluated the association between rs11077 polymorphism located in the 3’UTR of the XPO5 gene and cancer susceptibility. We conducted a meta-analysis to assess the impact of XPO5 rs11077 polymorphism on cancer risk. Materials and Methods: The online databases were searched for relevant case-control studies published up to July 2018. 15 articles of 16 studies, with totally 7284 cancer cases and 8511 healthy controls, were eligible for inclusion in the meta-analysis. The data were extracted from the eligible studies and were processed using Stata 14.1 and Revman 5.3 software. Pooled estimates of odds ratio with 95% confidence intervals were used to evaluate the strength of association between XPO5 rs11077 and cancer risk. Results: Overall, our finding showed no significant association between XPO5 rs11077 variant and overall cancer risk, either performed subgroup analysis by cancer types and ethnic groups in all genetic model. Conclusion: The findings did not support an association between rs11077 variant and cancer risk. Due to small sample sizes particularly in stratified analysis, further large-scale well designed studies between this polymorphism and cancer risk are warranted. Summary. Aim: Several studies evaluated the association between rs11077 polymorphism located in the 3’UTR of the XPO5 gene and cancer susceptibility. We conducted a meta-analysis to assess the impact of XPO5 rs11077 polymorphism on cancer risk. Materials and Methods: The online databases were searched for relevant case-control studies published up to July 2018. 15 articles of 16 studies, with totally 7284 cancer cases and 8511 healthy controls, were eligible for inclusion in the meta-analysis. The data were extracted from the eligible studies and were processed using Stata 14.1 and Revman 5.3 software. Pooled estimates of odds ratio with 95% confidence intervals were used to evaluate the strength of association between XPO5 rs11077 and cancer risk. Results: Overall, our finding showed no significant association between XPO5 rs11077 variant and overall cancer risk, either performed subgroup analysis by cancer types and ethnic groups in all genetic model. Conclusion: The findings did not support an association between rs11077 variant and cancer risk. Due to small sample sizes particularly in stratified analysis, further large-scale well designed studies between this polymorphism and cancer risk are warranted. PH Akademperiodyka 2023-06-02 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-13 10.32471/exp-oncology.2312-8852.vol-41-no-4.13811 Experimental Oncology; Vol. 41 No. 4 (2019): Experimental Oncology; 346-352 Експериментальна онкологія; Том 41 № 4 (2019): Експериментальна онкологія; 346-352 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-41-no-4 en https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-13/2019-4-13 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/
institution Experimental Oncology
baseUrl_str
datestamp_date 2023-10-11T16:42:06Z
collection OJS
language English
topic cancer
meta-analysis
risk
XPO5
spellingShingle cancer
meta-analysis
risk
XPO5
Moazeni-Roodi, A.
Taheri, M.
Hashemi, M.
Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
topic_facet cancer
meta-analysis
risk
XPO5
cancer
meta-analysis
risk
XPO5
format Article
author Moazeni-Roodi, A.
Taheri, M.
Hashemi, M.
author_facet Moazeni-Roodi, A.
Taheri, M.
Hashemi, M.
author_sort Moazeni-Roodi, A.
title Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_short Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_full Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_fullStr Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_full_unstemmed Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_sort association between xpo5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
title_alt Association between XPO5 rs11077 polymorphism and cancer susceptibility: a meta-analysis of 7284 cases and 8511 controls
description Summary. Aim: Several studies evaluated the association between rs11077 polymorphism located in the 3’UTR of the XPO5 gene and cancer susceptibility. We conducted a meta-analysis to assess the impact of XPO5 rs11077 polymorphism on cancer risk. Materials and Methods: The online databases were searched for relevant case-control studies published up to July 2018. 15 articles of 16 studies, with totally 7284 cancer cases and 8511 healthy controls, were eligible for inclusion in the meta-analysis. The data were extracted from the eligible studies and were processed using Stata 14.1 and Revman 5.3 software. Pooled estimates of odds ratio with 95% confidence intervals were used to evaluate the strength of association between XPO5 rs11077 and cancer risk. Results: Overall, our finding showed no significant association between XPO5 rs11077 variant and overall cancer risk, either performed subgroup analysis by cancer types and ethnic groups in all genetic model. Conclusion: The findings did not support an association between rs11077 variant and cancer risk. Due to small sample sizes particularly in stratified analysis, further large-scale well designed studies between this polymorphism and cancer risk are warranted.
publisher PH Akademperiodyka
publishDate 2023
url https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-13
work_keys_str_mv AT moazeniroodia associationbetweenxpo5rs11077polymorphismandcancersusceptibilityametaanalysisof7284casesand8511controls
AT taherim associationbetweenxpo5rs11077polymorphismandcancersusceptibilityametaanalysisof7284casesand8511controls
AT hashemim associationbetweenxpo5rs11077polymorphismandcancersusceptibilityametaanalysisof7284casesand8511controls
first_indexed 2025-07-17T12:16:44Z
last_indexed 2025-07-17T12:16:44Z
_version_ 1850411214167867392